On October 28, 2021, Hongri Pharmaceutical (300026.SZ) announced that in the first three quarters of 2021, the company achieved operating income of 5.486 billion yuan, an increase of 16.52% year-on-year; net profit attributable to shareholders of listed companies was 637 million yuan, an increase of 6.34% year-on-year. Among them, in the third quarter of 2021, the company achieved operating income of 2.000 billion yuan, an increase of 3.83% year-on-year; net profit attributable to shareholders of listed companies was 199 million yuan, down 21.98% year-on-year.
This article originated from Grand Gateway